Company Overview
OraSure Technologies, Inc. functions as a developer, manufacturer, and distributor of diagnostic products and specimen collection devices, serving markets across the United States, Europe, Africa, and other international regions. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, which implies a reliance on specialized manufacturing capabilities and regulatory compliance for medical-grade technologies. In terms of scale, OraSure Technologies, Inc. holds a market capitalization of $217.06M, generates $115.02M in annual revenue, and employs a workforce of 500 individuals. These valuation and revenue figures indicate that the company operates as a mid-sized entity with a significant but not dominant market presence, suggesting it holds a substantial niche in the global diagnostic testing landscape without commanding the massive capitalization of industry leaders.
Financial Health
The company reports a Trailing Twelve Months revenue of $115.02M, yet it simultaneously recorded a net income loss of $68,731,000 and an EBITDA of $-57,432,000 during the same period. The substantial gap between the positive revenue figure and the significant net income loss reveals a cost structure characterized by high operating expenses that exceed gross profits, indicating that the company is currently burning cash to sustain its operations. The firm reported a free cash flow of $-17,041,000, which signifies a lack of financial flexibility as the business generates more cash outflows than inflows, requiring external financing or cash reserves to fund ongoing activities. Margin analysis shows a gross margin of 41.9%, which indicates that the core manufacturing and sales of diagnostic kits retain a healthy portion of revenue before overhead, whereas the operating margin of -61.1% and profit margin of -59.8% highlight severe inefficiencies in covering fixed costs and generating bottom-line earnings. On the balance sheet, OraSure holds $199.28M in cash against $13.20M in debt, supported by a debt-to-equity ratio of 3.87, suggesting the company is currently leveraged but possesses a robust cash buffer to service obligations or invest in recovery. The current ratio stands at 6.58, indicating an extremely strong short-term liquidity position where current assets vastly outweigh current liabilities. Return on Equity is -18.3% and Return on Assets is -9.6%, metrics that reveal management is currently failing to generate positive returns on the capital invested by shareholders or utilized in asset generation.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the lack of net income, while the Forward P/E is -6.68, a negative figure that implies the market is pricing in expectations of future profitability or a continuation of current earnings losses. The price-to-book ratio is 0.65, indicating that the market values the company at a significant discount to its book value, suggesting investors are not paying a premium for the company's tangible assets. Using alternative metrics, the price-to-sales ratio is 1.89 and the EV/EBITDA is -0.54, which suggests the company is valued based on revenue generation rather than earnings power, reflecting the high risk associated with its negative cash flows. The stock has traded between a 52-week high of $4.22 and a 52-week low of $2.08, and based on the provided data, the current valuation context sits within this range, reflecting recent volatility. The beta is 0.86, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market fluctuations than the average large-cap healthcare stock.
Growth & Income
Revenue growth year-over-year is -28.5%, while earnings growth is N/A due to the company reporting a net loss; consequently, earnings are not growing faster than revenue because both are contracting or negative. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio of 0.0%, meaning it reinvests its earnings—or in this case, its cash reserves—into growth initiatives rather than returning capital to shareholders. This profile characterizes OraSure Technologies, Inc. as a high-risk, high-growth potential entity that forgoes current income distribution to fund its diagnostic product development and market expansion efforts. The overall growth and income profile is defined by significant revenue contraction and a complete absence of dividend income, positioning the asset primarily for capital appreciation potential rather than income generation.